{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:46:22Z","timestamp":1793119582200,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.clindermatol.2018.08.006","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T05:31:43Z","timestamp":1534397503000},"page":"765-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Use of antipsychotic drugs in dermatology"],"prefix":"10.1016","volume":"36","author":[{"given":"Madhulika A.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Vujcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana R.","family":"Pur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2018.08.006_bb0005","series-title":"Manual of Clinical Psychopharmacology","first-page":"185","article-title":"Antipsychotic drugs","author":"Schatzberg","year":"2015"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0010","series-title":"Chemotherapy in Psychiatry","author":"Baldessarini","year":"2013"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0015","series-title":"Massachusetts General Hospital Psychopharmacology and Neurotherapeutics","first-page":"72","article-title":"Antipsychotic drugs","author":"Freudenreich","year":"2016"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0020","series-title":"Use of antipychotic drugs in dermatology (MSc dissertation)","author":"Gupta","year":"2017"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0025","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jaad.2016.11.021","article-title":"Psychocutaneous disease: pharmacotherapy and psychotherapy","volume":"76","author":"Kuhn","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0035","series-title":"Comprehensive Dermatologic Drug Therapy","first-page":"375","article-title":"Psychotropic agents","author":"Bhutani","year":"2013"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0040","series-title":"Dermatology","first-page":"127","article-title":"Psychocutaneous diseases","volume":"vol 1","author":"Lee","year":"2012"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0045","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4088\/JCP.09m05114gre","article-title":"A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania","volume":"71","author":"Van Ameringen","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0050","first-page":"143","article-title":"Olanzapine is effective in the management of some self-induced dermatoses: three case reports","volume":"66","author":"Gupta","year":"2000","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/120347540000400310","article-title":"Treatment of self-mutilation with olanzapine","volume":"4","author":"Garnis-Jones","year":"2000","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0060","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2230.2012.04448.x","article-title":"Facial ulcer treated with olanzapine","volume":"38","author":"Lowry","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0065","series-title":"Clinical Handbook of Psychotropic Drugs","author":"Procyshyn","year":"2015"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaad.2012.04.007","article-title":"A survey assessment of the recognition and treatment of psychocutaneous disorders in the outpatient dermatology setting: how prepared are we?","volume":"68","author":"Gee","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM195502102520606","article-title":"Chlorpromazine treatment for relief of itching in severe refractory neurodermatitis","volume":"252","author":"Tilley","year":"1955","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11920-012-0284-9","article-title":"Clinically significant psychotropic drug-drug interactions in the primary care setting","volume":"14","author":"English","year":"2012","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0090","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00128071-200304090-00005","article-title":"Drug interactions of clinical significance for the dermatologist: recognition and avoidance","volume":"4","author":"Shapiro","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0095","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","article-title":"Clinically significant drug interactions with atypical antipsychotics","volume":"27","author":"Kennedy","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0100","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2165\/00128071-200203090-00005","article-title":"Adverse cutaneous reactions to antipsychotics","volume":"3","author":"Warnock","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clindermatol.2011.11.014","article-title":"Psychiatric medications: adverse cutaneous drug reactions","volume":"31","author":"Bliss","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0110","series-title":"Litt\u2019s Drug Eruptions and Reactions Manual: D.E.R.M","author":"Litt","year":"2013"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0115","first-page":"135","article-title":"Commonly used photosensitizing medications: their adverse effects and precautions to be considered","volume":"4","author":"Nayak","year":"2010","journal-title":"Int J Pharm Sci Rev Res"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0120","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/00007611-195912000-00015","article-title":"Trimeprazine therapy for physiologic and psychologic pruritus","volume":"52","author":"Ayd","year":"1959","journal-title":"South Med J"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0125","first-page":"332","article-title":"Ancillary therapy of dermatoses with perphenazine","volume":"56","author":"Fanburg","year":"1959","journal-title":"J Med Soc N J"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/archderm.1958.01560010121024","article-title":"A dermatologic and psychiatric study of perphenazine (trilafon) in dermatology","volume":"77","author":"Shanon","year":"1958","journal-title":"AMA Arch Derm"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0135","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2133.1961.tb14395.x","article-title":"Controlled trials of two oral antipruritic drugs, trimeprazine and methdilazine","volume":"73","author":"Smith","year":"1961","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0140","first-page":"155","article-title":"Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients","volume":"67","author":"Neifeld","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0145","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/1097-0142(19820315)49:6<1178::AID-CNCR2820490619>3.0.CO;2-H","article-title":"Effects of dopamine agonists and antagonists on murine melanoma: correlation with dopamine binding activity","volume":"49","author":"Krummel","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(79)91025-0","article-title":"Treatment of metastatic malignant melanoma with pimozide","volume":"1","author":"Taub","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0155","doi-asserted-by":"crossref","first-page":"673 e671","DOI":"10.1016\/j.jaad.2011.12.012","article-title":"Delusional infestation: clinical presentation in 147 patients seen at Mayo Clinic","volume":"67","author":"Foster","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/070674379504001008","article-title":"An overview of treatment in paranoia\/delusional disorder","volume":"40","author":"Munro","year":"1995","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2340\/00015555625558","article-title":"Delusions of infestation treated by pimozide: a double-blind crossover clinical study","volume":"62","author":"Hamann","year":"1982","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1192\/bjp.bp.106.029660","article-title":"Antipsychotic treatment of primary delusional parasitosis: systematic review","volume":"191","author":"Lepping","year":"2007","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0175","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1310\/hpj4902-134","article-title":"Pimozide: parasitosis (delusional)","volume":"49","author":"Generali","year":"2014","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0180","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1046\/j.1365-2133.1998.02272.x","article-title":"Delusions of parasitosis. A psychiatric disorder to be treated by dermatologists? An analysis of 33 patients","volume":"138","author":"Zomer","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0185","doi-asserted-by":"crossref","first-page":"h1328","DOI":"10.1136\/bmj.h1328","article-title":"How to approach delusional infestation","volume":"350","author":"Lepping","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0190","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JCP.0b013e318185e774","article-title":"Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy","volume":"28","author":"Freudenmann","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0195","article-title":"Pimozide for schizophrenia or related psychoses","volume":"11","author":"Mothi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0200","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000284934","article-title":"100 years of delusional parasitosis: meta-analysis of 1,223 case reports","volume":"28","author":"Trabert","year":"1995","journal-title":"Psychopathology"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2133.1981.tb00746.x","article-title":"Dermatological non-disease: a common and potentially fatal disturbance of cutaneous body image","volume":"104","author":"Cotterill","year":"1981","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0210","article-title":"Pharmacotherapy and psychotherapy for body dysmorphic disorder","volume":"1","author":"Ipser","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0215","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1176\/appi.ajp.162.5.1022-a","article-title":"Olanzapine augmentation of fluoxetine in body dysmorphic disorder","volume":"162","author":"Phillips","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0220","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.162.2.377","article-title":"Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder","volume":"162","author":"Phillips","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0225","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/archderm.1985.01660060094029","article-title":"The dysmorphic syndrome","volume":"121","author":"Koblenzer","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0230","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4088\/JCP.v62n0413e","article-title":"Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report","volume":"62","author":"Grant","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0235","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1017\/S0790966700009277","article-title":"Body dysmorphic disorder treated with venlafaxine, olanzapine and cognitive behavioural therapy","volume":"22","author":"McWilliams","year":"2005","journal-title":"Ir J Psychol Med"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0240","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1440-1819.2008.01813.x","article-title":"Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder","volume":"62","author":"Nakaaki","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0245","first-page":"286","article-title":"Treatment with risperidone and venlafaxine of a patient with double-coded diagnosis of body dysmorphic disorder and delusional disorder somatic type","volume":"15","author":"Goulia","year":"2011","journal-title":"Hippokratia"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0250","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/da.10034","article-title":"Trichotillomania and skin-picking: a phenomenological comparison","volume":"15","author":"Lochner","year":"2002","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0255","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.comppsych.2004.03.010","article-title":"Dissociative experiences in obsessive-compulsive disorder and trichotillomania: clinical and genetic findings","volume":"45","author":"Lochner","year":"2004","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007662.pub2","article-title":"Pharmacotherapy for trichotillomania","author":"Rothbart","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.genhosppsych.2016.04.001","article-title":"A systematic review and meta-analysis of psychiatric treatments for excoriation (skin-picking) disorder","volume":"41","author":"Selles","year":"2016","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0270","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/070674370905400507","article-title":"Obsessive-compulsive spectrum disorders: a review of the evidence-based treatments","volume":"54","author":"Ravindran","year":"2009","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0275","first-page":"29","article-title":"Augmentation of venlafaxine with aripiprazole in a case of treatment-resistant excoriation disorder","volume":"11","author":"Turner","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1752-1947-6-219","article-title":"Haloperidol augmentation of fluvoxamine in skin picking disorder: a case report","volume":"6","author":"Luca","year":"2012","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0285","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.4088\/JCP.v67n0821f","article-title":"Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation","volume":"67","author":"Carter","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0290","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/070674370404901121","article-title":"Olanzapine augmentation of fluoxetine in the treatment of pathological skin picking","volume":"49","author":"Christensen","year":"2004","journal-title":"Can J Psychiatr"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0295","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/10401230701465277","article-title":"The treatment of psychogenic excoriation and obsessive compulsive disorder using aripiprazole and fluoxetine","volume":"19","author":"Curtis","year":"2007","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0300","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2004.06151.x","article-title":"Efficacy of olanzapine in the treatment of psychogenic excoriation","volume":"151","author":"Blanch","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0305","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/120347540100500106","article-title":"Olanzapine may be an effective adjunctive therapy in the management of acne excoriee: a case report","volume":"5","author":"Gupta","year":"2001","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0310","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2230.2006.02094.x","article-title":"Olanzapine therapy for subacute prurigo","volume":"31","author":"Hyun","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0315","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2230.1983.tb01746.x","article-title":"Acne excoriee: a protective device","volume":"8","author":"Sneddon","year":"1983","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0320","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0163-8343(87)90101-0","article-title":"The self-inflicted dermatoses: a critical review","volume":"9","author":"Gupta","year":"1987","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0325","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ad.2012.10.004","article-title":"Dermatitis artefacta: a review","volume":"104","author":"Rodr\u00edguez Pichardo","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0330","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjd.12416","article-title":"Dermatitis artefacta and artefactual skin disease: The need for a psychodermatology multidisciplinary team to treat a difficult condition","volume":"169","author":"Mohandas","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0335","first-page":"1","article-title":"The current management of delusional parasitosis and dermatitis artefacta","volume":"15","author":"Koblenzer","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0340","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000049672","article-title":"Periocular and perioral artefactual dermatitis: dermatological and psychiatric management in a hospital setting","volume":"2","author":"Pascual","year":"2001","journal-title":"Dermatol Psychosom"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0345","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00128071-200001010-00005","article-title":"Dermatitis artefacta. Clinical features and approaches to treatment","volume":"1","author":"Koblenzer","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0350","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2340\/00015555-1400","article-title":"European guideline on chronic pruritus","volume":"92","author":"Weisshaar","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0355","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14728214.2015.1051964","article-title":"Emerging drugs for the treatment of pruritus","volume":"20","author":"Stander","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0360","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ejp.766","article-title":"An evidence-based review of systemic treatments for itch","volume":"20","author":"Pongcharoen","year":"2016","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0365","article-title":"Pharmacological interventions for pruritus in adult palliative care patients","volume":"11","author":"Siemens","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0370","first-page":"95","article-title":"A new sedative and antipruriginous medicament","volume":"60","author":"Pellerat","year":"1953","journal-title":"Bull Soc Fr Dermatol Syphiligr"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0375","first-page":"101","article-title":"Clinical management of pruritus","volume":"13","author":"Stander","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0380","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jpainsymman.2003.12.008","article-title":"Use of thioridazine in palliative care patients with troublesome sweating","volume":"27","author":"Abbas","year":"2004","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0385","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3122\/jabfm.2012.06.120033","article-title":"Night sweats: a systematic review of the literature","volume":"25","author":"Mold","year":"2012","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0390","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0885-3924(03)00141-6","article-title":"Flushing and sweating in an advanced breast cancer patient relieved by olanzapine","volume":"25","author":"Zylicz","year":"2003","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0395","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1365-2133.2010.09969.x","article-title":"Quetiapine in the treatment of hyperhidrosis axillaris","volume":"163","author":"Dickmann","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0400","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archderm.1986.01660200024007","article-title":"Calmodulin inhibitor therapy in psoriasis","volume":"122","author":"Humbert","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2018.08.006_bb0405","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000256166","article-title":"Psoriasis and stress","volume":"113","author":"Reiss","year":"1956","journal-title":"Dermatologica"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X18301779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X18301779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T10:59:33Z","timestamp":1693825173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X18301779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0738081X18301779"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2018.08.006","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of antipsychotic drugs in dermatology","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2018.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}